BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2016 10:43:00 AM | Browse: 384 | Download: 405
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 25905
Country/Territory Japan
Received
2016-03-26 16:42
Peer-Review Started
2016-03-26 18:14
To Make the First Decision
2016-06-06 17:24
Return for Revision
2016-06-07 17:12
Revised
2016-06-21 05:14
Second Decision
2016-07-11 11:59
Accepted by Journal Editor-in-Chief
2016-07-11 12:07
Accepted by Company Editor-in-Chief
2016-07-22 11:11
Articles in Press
2016-07-22 11:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-08-28 09:29
Publish the Manuscript Online
2016-09-12 10:43
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Role of targeted therapy in metastatic colorectal cancer
Manuscript Source Invited Manuscript
All Author List Yoshihito Ohhara, Naoki Fukuda, Satoshi Takeuchi, Rio Honma, Yasushi Shimizu, Ichiro Kinoshita and Hirotoshi Dosaka-Akita
Funding Agency and Grant Number
Corresponding author Yoshihito Ohhara, MD, Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan. yoshihito-ohhara@kkr-smc.com
Keywords Metastatic colorectal cancer; Aflibercept; Ramucirumab; Regorafenib; Cetuximab; Panitumumab; Targeted therapy; Bevacizumab
Core Tip The development of molecular targeted agents contributes to prolonging survival of patients with metastatic colorectal cancer (mCRC). One anti-vascular endothelial growth factor agent, bevacizumab, and two anti-epidermal growth factor receptor (EGFR) agents, cetuximab and panitumumab, have demonstrated clinical benefits in first-line, second-line, or salvage therapy in combination with cytotoxic chemotherapy. Moreover, RAS mutation has been proven to be a negative biomarker for anti-EGFR therapy in recent retrospective analyses. This article summarizes the evidence from large clinical trials and highlights the benefit of the molecular targeted agents in patients with mCRC.
Publish Date 2016-09-12 10:43
Citation Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
Url http://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI http://dx.doi.org/10.4251/wjgo.v8.i9.642
Full Article (PDF) WJGO-8-642.pdf
Full Article (Word) WJGO-8-642.doc
Manuscript File 25905-Review.docx
Answering Reviewers 25905-Answering reviewers.pdf
Audio Core Tip 25905-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 25905-Conflict-of-interest statement.pdf
Copyright License Agreement 25905-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 25905-Language certificate.pdf
Peer-review Report 25905-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 25905-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 25905-Scientific misconduct check.pdf
Scientific Editor Work List 25905-Scientific editor work list.pdf